252 related articles for article (PubMed ID: 30402905)
1. Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study.
Kao HH; Kao LT; Li IH; Pan KT; Shih JH; Chou YC; Wu ST
J Clin Pharmacol; 2019 Mar; 59(3):335-343. PubMed ID: 30402905
[TBL] [Abstract][Full Text] [Related]
2. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
[TBL] [Abstract][Full Text] [Related]
4. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.
Wang LH; Liu CK; Chen CH; Kao LT; Lin HC; Huang CY
Andrology; 2016 Jan; 4(1):128-32. PubMed ID: 26711703
[TBL] [Abstract][Full Text] [Related]
5. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study.
Wu FJ; Li IH; Chien WC; Shih JH; Lin YC; Chuang CM; Cheng YD; Kao LT
BMJ Open; 2020 Mar; 10(3):e034202. PubMed ID: 32213519
[TBL] [Abstract][Full Text] [Related]
7. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
8. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.
Kao LT; Lin HC; Chung SD; Huang CY
Asian J Androl; 2017; 19(4):414-417. PubMed ID: 27232853
[TBL] [Abstract][Full Text] [Related]
9. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
Tsai HT; Pfeiffer RM; Philips GK; Barac A; Fu AZ; Penson DF; Zhou Y; Potosky AL
J Urol; 2017 May; 197(5):1251-1257. PubMed ID: 27993663
[TBL] [Abstract][Full Text] [Related]
10. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
11. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
Schmid M; Hanske J; Ravi P; Krishna N; Reznor G; Meyer CP; Fisch M; Noldus J; Nguyen PL; Trinh QD
Int J Urol; 2016 Apr; 23(4):305-11. PubMed ID: 26763083
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
13. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients.
Liu JM; Liu DW; Chuang HC; Wu CT; Lin CY; Hsu RJ
Int Urol Nephrol; 2019 Jul; 51(7):1113-1119. PubMed ID: 31111393
[TBL] [Abstract][Full Text] [Related]
15. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
16. Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer.
Hicks BM; Klil-Drori AJ; Yin H; Campeau L; Azoulay L
Epidemiology; 2017 Sep; 28(5):712-718. PubMed ID: 28768300
[TBL] [Abstract][Full Text] [Related]
17. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
[TBL] [Abstract][Full Text] [Related]
18. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer.
Liu JM; Chen TH; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):276-283. PubMed ID: 30337635
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer.
Wu FJ; Kao LT; Sheu SY; Lin HC; Chung SD
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28786220
[TBL] [Abstract][Full Text] [Related]
20. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]